PLBI

[stockplaya321]

PLBI- is starting to make a comeback- stock I hear is going to have a great run next week- also hasnt had news in awhile and I hear it will be running another campagin -Time to get in on this one- while stock is cheap and make some money on this company-GL to all!

Proton Laboratories Inc., (PLBI.PK), through Regenobody S.A. ("Regenobody"), a Dominican Republic ("DR") company has been licensed by the DR government to investigate, experiment, treat and develop autologus stem cells for regenerating one's own cellular tissues. Regenobody has the exclusive rights in its territory to the RNL BIO Company Ltd. of Korean systems and equipment for the banking, manufacture and right to purchase stem cells from RNL-BIO for a period of 20 years

[RAZOR11]

PLBI, Here is one to watch. Stock is trading like news is coming. It is three times the ten day and is +20% today so far. There has been a little chatter about this stock having a run again next week. I have looked at the charts on this one and there is very weak resistace holding this one back and we are already above the 20, 50 and 200 day MA. We coulld see some nice gains on this one. Remember to do your own dd. Good luck to you all

[stockplaya321]

Proton Laboratories Inc., (PLBI.PK), through Regenobody S.A. ("Regenobody"), a Dominican Republic ("DR") company has been licensed by the DR government to investigate, experiment, treat and develop autologus stem cells for regenerating one's own cellular tissues. Regenobody has the exclusive rights in its territory to the RNL BIO Company Ltd. of Korean systems and equipment for the banking, manufacture and right to purchase stem cells from RNL-BIO for a period of 20 years. The license extends to all of the Caribean, Central and South America. RNL-

[gucci88]

PLBI proton labs. inc, is a standout stock imo, recently announced that they will have an acquisition of regenobody S.A a company in the Dominican Republic highly involved in the lasted technological breakthroughs in Stem cell regeneration using patients own cells.
Pursuant to the Agreement, the Company (PLBI) will issue 300,000,000 of its common shares to the Regenobody shareholders, which will result in the shareholders of Regenobody acquiring shareholder control of Proton Laboratories, Inc.
aggressively work toward completing the development of its laboratory and acquisition of the balance of the needed equipment from its Korean licensor and patent holder, RNLBIO. It is anticipated that a name change and symbol change will occur in the next 90 days. It's been a little over 90 days and imo, something should be shaping up very soon. Well, i honestly think PLBI is set up for a run. test indicators Bollinger bands expanding, may see some volatility spiking with some price shifting. SAR reversal ind. @ .0196 and descending. currently testing .015 range cud see a big force play if reversal fills.

[GreenGiant]

PLBI/RegenoBody Announces Filing of Additional Information on OTC Markets.com

[GreenGiant]

PLBI-REGENOBODY S.A., a wholly owned subsidiary of Proton Laboratories, Inc., brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options with special Stem Cell Therapies utilizing the most potent cells in the world, today. Therapies are tailored for each individual, based upon their specific needs. Cells are obtained by the most modern technologic method. Their transplant physicians and stem cell laboratory scientists, in conjunction with RNL Bio, have been regarded as the best in the world. Stem cells derived from Autologous (Stem cells taken from your own body) and Allogeneic (Stem cells from a source other than your own) are used depending on the particular condition that needs to be treated. Treatments are delivered by an experienced team of International and U.S. Board Certified Physicians who are guided by strict protocols ensuring excellence in medical care.

[GreenGiant]

--------------------------------------------------------------------------------

PLBI - The next one to move into

REGENOBODY IS A WORLD LEADER IN STEM CELLS TREATMENTS

By applying the regenerative powers of stem cells, REGENOBODY AGE REVERSAL achieves the target of halting the ageing degenerative process, improving the quality of life of people willing to maintain a young look and a real rejuvenation in the inside, with better functioning, re-energized and healthy organs.


REGENOBODY THERAPEUTIC brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options.


Many different conditions can be successfully addressed using their special Stem Cell Therapies. Their institute utilizes the most potent cells in the world, today. Therapies are tailored for each individual, based upon their specific needs. Cells

[GreenGiant]

PROTON LABORATORIES, INC. (PLBI)
Proton Laboratories, Inc., through the acquisition of Regenobody S.A., a Dominican Republic company, is involved in some of the latest technologies associated with stem cell regeneration using the patient's own stem cells.
Recent Price Last
0.01
Market Capitalization $1.08M
Est Float 36M
Outstanding Shares 56M
Quotation OTC.PK

Proton Laboratories, Inc.

1135 Atlantic Avenue
Alameda, CA 94501



Phone: 888-548-3002
Fax: 888-548-3004
Similar Companies in Sector

[stockplaya321]

Adult Stem Cell Therapy is safe, highly effective and presents minimal risk. It begins with a complete medical evaluation performed by the patient's personal doctor, who will use the necessary documentation sent by them, to determine the patient's overall health and eligibility for therapy.

Once qualified, Adult Stem Cells are extracted from the patient's own blood and/or fat, via a standard draw procedure. Since it is the patient's own cells, there is no possibility of the body rejecting its own stem cells. This makes the procedure very safe and non-controversial. The few naturally occurring stem cells are then cultivated into millions of RegenoCells.

The RegenoCell are then sent to their Clinics in Sosua and re-injected back into the patient's via an IV or IM i
marketwatch47: PLBI- Take a look!
This is a great and interseting company to get into. Stem-cell research is really big right now and this company seems to be making progress- I have made gains off of it as well. hearing stock is about to have a huge run-

Stem Cell Therapy

Adult Stem Cell Therapy is safe, highly effective and presents minimal risk. It begins with a complete medical evaluation performed by the patient's personal doctor, who will use the necessary documentation sent by them, to determine the patient's overall health and eligibility for therapy.

Once qualified, Adult Stem Cells are extracted from the patient's own blood and/or fat, via a standard draw procedure. Since it is the patient's own cells, there is no possibility of the body rejecting its own stem cells.

[RAZOR11]

PLBI not much volume today but lots of rumors about news coming on this one soon. I think it is going to be big like back in january. This thing exploded from .002 to .02 in no time. We are at a good entry price and have strong support holding us up and weak resistance until we hit .014 which is the 20 day MA. I think we will break through that and the 50 day MA we might bounce back off or have a hard time breaking through that one. Lets see what happens when the news hits the wire. Remember to do your own dd Good luck to you all!!

[RAZOR11]

PLBI, Keep this one on your radar list. News came out after the close yesterday and this morning had some nice prebuys. This is going to have some nice volume and some nice gains today. Good news make this one fly. This afternoon this is going to explode. Take a position while the price is still low. Good luck here is the latest news..

SOSUA BAY, Dominican Republic, May 11, 2010 (GLOBE NEWSWIRE) -- Proton Laboratories, Inc. (Pink Sheets:PLBI - News) announced today that following its success in attaining exclusive rights for RNL Bio Company Ltd's licenses, technology and equipment which allows PLBI's wholly owned subsidiary, RegenoBody, S.A. to treat anyone within the Caribbean, Central and/or South America, that the laboratory needed to perform the work is being designed by RNL Bio for shipment to the RegenoBody facility in the Dominican Republic. The laboratory will be designed according to the specifications required of RNL Bio in Korea so that it can duplicate the success of RNL Bio in regenerating human stem cells.


The initial concept of bringing what was once stereotyped as a controversial treatment to this hemisphere was based upon more than a year of research and the actual treatment and successful results of PLBI's President, Armando Casciati. After Mr. Casciati's treatment, he acquired the majority control of PLBI.pk, in an effort to accelerate the process of bringing stem cell technology to the Western Hemisphere.


Mr. Casciati stated, "Entrepreneurs typically look merely for profit opportunities. I am proud to have found such an incredible life opportunity which will help serve the public with some of the latest technological advances in medical history. I believe our alliance with RNL Bio Company will prove to be a life changing opportunity for our clients, as it has been for me."


RNL Bio Company LTD is considered a leader in stem cell technology with a wealth of treatments. After years of investment and research, RNL has developed technology ranging from cosmetic and arthritic needs to spinal cord injury and cancer treatments.


Korean FDA approved RNL's human clinical study to treat patients with spinal cord injury using 'RNL-Astrostem' that is based on fat derived adult stem cells.


In early 2009, RNL Bio publicly presented its three years' preclinical trial results showing a perfect safety profile and remarkable efficacy potential. RNL was approved by the Korean government to begin phase I human trial using these adult stem cells and we believe it is the world's first trial to treat spinal cord injury with adult stem cells derived from a patients' own fat tissue.


Since the Korean FDA approval, RNL Bio has progressively increased the utility of its RNL-Astrostem technology. RNL-Astrostem is administered by intravenous infusion so patients don't have to worry about any invasive and painful surgical procedure. Dr. Jeong Chan Ra, CEO of RNL Bio, said, "Our stem cell therapeutics involves no immune rejection because the stem cells are exactly the patient's own. Our adult stem cell has no tumorigenicity activity at all while embryonic stem cell faces high risk of it. We have developed the safest therapeutics to help devastated patients with incurable diseas

[stocksalot]

SOSUA BAY, Dominican Republic, May 13, 2010 (GLOBE NEWSWIRE) -- Proton Laboratories, Inc. (Pink Sheets:PLBI - News) announced today that Armando Casciati has signed and authorized the filing of an amendment to the Articles of Incorporation of the Company whereby his Series B Preferred Convertible Stock rights are changed. The change will eliminate his right to convert his 19,600,000 preferred shares into 1,000 shares of common for each preferred and will essentially grant him a super voting share holding position which will be able to convert into 55% of the common stock when combined with his common holdings. As of the date of this release, the conversion right would not affect any shareholders since Mr. Casciati currently owns approximately 70% of the issued common shares currently outstanding.



In addressing this matter Mr. Casciati stated, "It was never my intent to have the Preferred Shares designated in the manner that they were issued. Former management had authorized and filed the designation as it was shown on our information statement. This new amendment and designation corrects the agreement that was made at the time of our being acquired by Proton Laboratories, Inc. and eliminates the huge overhang in the market that the prior designation created. The Amendment was filed last week and should be available for retrieval in the next 7 days."



About Proton Laboratories, Inc. and its wholly owned subsidiary RegenoBody S.A:



RegenoBody S.A., a wholly owned subsidiary of Proton Laboratories, Inc., brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options with special Stem Cell Therapies utilizing the most potent cells in the world today. Therapies are tailored for each individual, based upon their specific needs. Cells are obtained by the most modern technologic method. Their transplant physicians and stem cell laboratory scientists, in conjunction with RNL Bio, have been regarded as the best in the world. Stem cells derived from Autologous (Stem cells taken from your own body) and Allogeneic (Stem cells from a source other than your own) are used depending on the particular condition that needs to be treated. Treatments are delivered by an experienced team of International and U.S. Board Certified Physicians who are guided by strict protocols ensuring excellence in medical care.

[RAZOR11]

Keep this on your radar list. Rumors of huge news after the bell today. Next week were going to see some big gains on this one and a huge volume spike on monday morning. Looking at the charts we have strong support at .009 and were not seeing any resistance till ..012 and in my opinion were going to break right through that and see .0195 or higher. The Mac D line is Curving north and could pass the signal line and when this happen this is going to explode.Keep watching this one and good luck to u all!!

[underdog442]

Proton Laboratories, Inc./RegenoBody Announces Delivery of Lab to Sosua Site

Share
retweet
EmailPrint..Companies:Proton Laboratories, Inc..Related Quotes
Symbol Price Change
PLBI.PK 0.01 0.00


{"s" : "plbi.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: Proton Laboratories, Inc. On Monday September 20, 2010, 9:00 am

SOSUA BAY, Dominican Republic, Sept. 20, 2010 (GLOBE NEWSWIRE) -- Proton Laboratories, Inc. (Pink Sheets:PLBI - News) CEO, Armando Casciati, announced today that the clean lab modular system has been released from customs and delivered to the laboratory site across the street from the clinic in a standalone facility. "We expect the lab to be installed and the remaining two pieces of equipment to be delivered by the end of October," stated Mr. Casciati. Mr. Casciati went on to say that "we are taking every precaution to construct this laboratory to the standards needed to safeguard the process of stem cell regeneration and with the supervision of Dr. Lee, we are confident that it will be done properly. Once a patient's fatty tissue stem cells are removed and analyzed, the lab will be the key factor in the regeneration of new stem cells from clients and therefore must be processed in a very clean, secure environment with detailed record keeping and culture identification. The lab will also be the key in new research and development projects that may be presented.



About Proton Laboratories, Inc. and its wholly owned subsidiary RegenoBody S.A:



RegenoBody S.A., a wholly owned subsidiary of Proton Laboratories, Inc., brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options with special Stem Cell Therapies utilizing the most effective cell regeneration techniques. Therapies are tailored for each individual, based upon their specific needs. Cells are obtained by the most modern technologic methods. The transplant physicians and stem cell laboratory scientists, associated with RNL Bio have been regarded as some of the best in the world. Stem cells derived from Autologous (Stem cells taken from your own body) and Allogeneic (Stem cells from a source other than your own) are used depending on the particular condition that needs to be treated. Treatments will be delivered by an experienced team of International and U.S. Board Certified Physicians who are guided by strict protocols ensuring excellence in medical care.



About RNL Bio Company LTD:



RNL Bio is a premier biopharmaceutical company focused on development and commercialization of adult stem cell therapeutics and dog cloning technology. Headquartered in Seoul with state-of-the-art GMP facility, RNL is publicly traded company on the Korea Exchange (Code 003190) and strives to become a global leader across the biomedical industry.